Our findings suggest that the combination of circulating cytokine CXCL12 levels and PD-L1 status can predict the survival of advanced NSCLC patients treated with ICIs, regardless of monotherapy or chemoimmunotherapy. This evidence concerns the gene CXCL12 and non-small cell lung carcinoma.